Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 875-881

  Semenas, Julius ^a   Dizeyi, Nishtman ^a   Persson, Jenny Liao ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Castration resistant prostate cancer; Clinical trials; Drug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; CABAZITAXEL; CYPROTERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE; PLACEBO; PREDNISONE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIANDROGEN THERAPY; ARTHRITIS; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; METASTASIS; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEIZURE; SURVIVAL RATE;

CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIALS; DRUG RESISTANCE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84883249583     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S45703     Document Type: Review

References (55)

1. GLOBOCAN v1.2 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2008.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets. 2012;13(10):1308-1323.
4. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;167(2 Pt 2):948-951; discussion 952.
5. Huggins C. The hormone-dependent cancers. JAMA. 1963;186: 481-483.
6. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1:S3-S8.
7. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85.
8. National Cancer Institute [homepage on the Internet]. Prostate cancer. National Institutes of Health; 2012. Available from: http://cancer.gov/cancertopics/wyntk/prostate. Accessed June 5, 2013.
9. Crawford ED, Eisenberger MA, McLeod DG, etal. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424.
10. Eisenberger MA, Blumenstein BA, Crawford ED, etal. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-1042.
11. Crawford ED. Combined androgen blockade. Urology. 1989; 34(4 Suppl):22-26; discussion 46-56.
12. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311(20):1281-1286.
13. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol. 1997;158(4):1623-1624.
14. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781-1788.
15. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355(9214):1491-1498.
16. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10(4):241-253.
17. Holzbeierlein J, Lal P, LaTulippe E, etal. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164(1):217-227.
18. Shah RB, Mehra R, Chinnaiyan AM, etal. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209-9216.
19. Tamura K, Furihata M, Tsunoda T, etal. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007;67(11):5117-5125.
20. Koivisto P, Kononen J, Palmberg C, etal. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57(2):314-319.
21. Chen CD, Welsbie DS, Tran C, etal. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33-39.
22. Stanbrough M, Bubley GJ, Ross K, etal. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815-2825.
23. Montgomery RB, Mostaghel EA, Vessella R, etal. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11): 4447-4454.
24. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12-23.
25. Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A. 1998;95(10):5527-5532.
26. Yeh S, Kang HY, Miyamoto H, etal. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine. 1999;11(2): 195-202.
27. Gregory CW, He B, Johnson RT, etal. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61(11):4315-4319.
28. Tran C, Ouk S, Clegg NJ, etal. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.
29. Wang Q, Li W, Zhang Y, etal. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138(2):245-256.
30. Clegg NJ, Wongvipat J, Joseph JD, etal. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503.
31. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-8261.
32. Petrylak DP, Tangen CM, Hussain MH, etal. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
33. Tannock IF, de Wit R, Berry WR, etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
34. de Bono JS, Oudard S, Ozguroglu M, etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
35. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327study. J Clin Oncol. 2008;26(2):242-245.
36. Darshan MS, Loftus MS, Thadani-Mulero M, etal. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011; 71(18):6019-6029.
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
38. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 2004;5(3): 158-164.
39. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003;22(56):9075-9086.
40. Metzger E, Wissmann M, Yin N, etal. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436-439.
41. Kahl P, Gullotti L, Heukamp LC, etal. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66(23):11341-11347.
42. Culig Z, Hoffmann J, Erdel M, etal. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81(2): 242-251.
43. Nguyen TV, Yao M, Pike CJ. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection. Endocrinology. 2007;148(6):2936-2943.
44. Medivation. Medivation's MDV3100 shown to be effective in a preclinical model of hormone-refractory prostate cancer [press release]. San Francisco, CA: Medivation; 2007 [February 26]. Available from: http://investors.medivation.com/releasedetail.cfm?ReleaseID=231214. Accessed June 5, 2013.
45. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12):3876-3883.
46. US Food and Drug Administration. Enzalutamide (XTANDI capsules). Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm. Accessed June 5, 2013.
47. XTANDI [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2012.
48. ClinicalTrials. gov. Available from: http://www.clinicaltrials.gov/ct2/home. Accessed 1 July, 2013.
49. Scher HI, Beer TM, Higano CS, etal. Antitumour activity of MDV3100in castration-resistant prostate cancer: a phase 1-2study. Lancet. 2010;375(9724):1437-1446.
50. Scher HI, Beer TM, Higano CS, etal. Phase I-II study of MDV3100in castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009;27: abstract 151.
51. ClinicalTrials. Current clinical trials for MDV3100. 2012; http://www.clinicaltrials.gov/ct2/results?term=MDV3100&recr=&rslt=&type=Intr&cond=&intr=&outc=&spons=Astellas&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=0&phase=1&phase=2&phase=3&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed March 14, 2012.
52. Scher HI, Fizazi K, Saad F, etal. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13): 1187-1197.
53. de Bono JS, Logothetis CJ, Molina A, etal. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21): 1995-2005.
54. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2): 483-489.
55. Kantoff PW, Higano CS, Shore ND, etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5): 411-422.